NASDAQ : MGX
Metagenomi Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 0.7803 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 29.48M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 29.48M |
| Enterprise Value | -53.47M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 37.78M |
| Shares Outstanding | 37.78M |
| Shares Change (YoY) | +1.07% |
| Shares Change (QoQ) | +0.21% |
| Owned by Insiders (%) | 10.57% |
| Owned by Institutions (%) | 17.12% |
| Float | 25.54M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.17 |
| Forward PS | 3.13 |
| PB Ratio | 0.26 |
| P/TBV Ratio | 0.26 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 4.50 |
| Quick Ratio | 4.40 |
| Debt / Equity | 0.34 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -60.61% |
| Return on Assets (ROA) | -28.19% |
| Return on Invested Capital (ROIC) | -32.31% |
| Return on Capital Employed (ROCE) | -68.85% |
| Weighted Average Cost of Capital (WACC) | 3.56% |
| Revenue Per Employee | $120,009 |
| Profits Per Employee | -$827,097 |
| Employee Count | 113 |
| Asset Turnover | 0.06 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | -190,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.70 |
| 52-Week Price Change | -66.80% |
| 50-Day Moving Average | 1.04 |
| 200-Day Moving Average | 1.29 |
| Relative Strength Index (RSI) | 31.15 |
| Average Volume (20 Days) | 169,773 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 1.29M |
| Short Previous Month | 1.27M |
| Short % of Shares Out | 3.42% |
| Short % of Float | 5.06% |
| Short Ratio (days to cover) | 7.84 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 13.56M |
| Gross Profit | -75.04M |
| Operating Income | -100.57M |
| Pretax Income | -93.65M |
| Net Income | -93.46M |
| EBITDA | -95.40M |
| EBIT | -100.57M |
| Loss Per Share | -$2.49 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 120.66M |
| Total Debt | 37.72M |
| Net Cash | 82.94M |
| Net Cash Per Share | $2.20 |
| Equity (Book Value) | 112.57M |
| Book Value Per Share | 2.98 |
| Working Capital | 96.84M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -85.49M |
| Capital Expenditures | -309,000 |
| Depreciation & Amortization | 5.16M |
| Net Borrowing | n/a |
| Free Cash Flow | -85.80M |
| FCF Per Share | -$2.27 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | -741.58% |
| Pretax Margin | -690.60% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -1.07% |
| Shareholder Yield | -1.07% |
| Earnings Yield | -319.26% |
| FCF Yield | -291.06% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $7.00 |
| Price Target Difference | 797.09% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | -43.85% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -3.42 |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |